A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD

Chest

Volumn 149, Issue 5, 2016, Pages 1181-1196

  Calzetta, Luigino ^a   Rogliani, Paola ^a   Matera, Maria Gabriella ^b   Cazzola, Mario ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Combination therapy; COPD; Long acting b2 agonist (LABA); Long acting muscarinic antagonist (LAMA)

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; LONG ACTING MUSCARINIC ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UNCLASSIFIED DRUG; VILANTEROL; BRONCHODILATING AGENT;

ARTICLE; BRONCHODILATATION; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRY POWDER INHALER; FORCED EXPIRATORY VOLUME; HEART DISEASE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY; SCORING SYSTEM; SOFT MIST INHALER; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; COMBINATION DRUG THERAPY; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84966586570     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.02.646     Document Type: Article

References (48)

1. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.org/. Accessed March 16, 2016.
2. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191.
3. National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. NICE guidelines [CG101]. London: NICE; 2010. http://guidance.nice.org.uk/CG101/Guidance/pdf/English. Accessed March 16, 2016.
4. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012;21(1):101-108.
5. Cazzola M, Calzetta L, Page CP, et al. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur J Pharmacol. 2014;745:135-143.
6. Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2015;12(2):175-181.
7. Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside. Respir Med. 2015;109(10):1305-1311.
8. Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015;761:168-173.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA Statement. Open Med. 2009;3(3):e123-e130.
10. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6): 932-946.
11. Shariff SZ, Bejaimal SA, Sontrop JM, et al. Retrieving clinical evidence: a comparison of PubMed and Google Scholar for quick clinical searches. J Med Internet Res. 2013;15(8):e164.
12. Kew KM, Dias S, Cates CJ. Long-Acting inhaled therapy (beta-Agonists, anticholinergics and steroids) for COPD: a network meta-Analysis. Cochrane Database Syst Rev. 2014;3:CD010844.
13. Horita N, Kaneko T. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. Int J Chron Obstruct Pulmon Dis. 2015;10:813-822.
14. Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD-role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmo. Dis. 2014;9: 687-695.
15. Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K. Once-daily long-Acting beta-Agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct Pulmon Dis. 2014;9: 813-824.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1): 1-12.
17. Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119-1129.
18. Sterne JA, Egger M. Funnel plots for detecting bias in meta-Analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046-1055.
19. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
20. Borenstein M. Introduction to Meta-Analysis. Chichester, UK: John Wiley & Sons; 2009.
21. DeCoster J. Meta-Analysis notes. http://www.stat-help.com/meta.pdf. Accessed March 16, 2016.
22. Turner JR, Durham TA. Metamethodology: conducting and reporting meta-Analyses. J Clin Hypertens (Greenwich). 2014;16(2):91-93.
23. Cazzola M, Calzetta L, Page C, et al. Influence of N-Acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-Analysis. Eur Respir Rev. 2015;24(137):451-461.
24. Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and endusers: R as a computational back-end. J Stat Software. 2012;49(5):1-15.
25. Viechtbauer W. Conducting metaanalyses in R with the metafor package. J. Stat. Software. 2012;36(3):1-48.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-Analyses. BMJ. 2003;327(7414): 557-560.
27. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
28. D'Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123.
29. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969-979.
30. ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat((R)) and tiotropium HandiHaler((R)) in patients with COPD: results of two randomized, double-blind, activecontrolled studies. Int J Chron Obstruct Pulmon Dis. 2014;9:1133-1144.
31. Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109:1312-1319.
32. Mahler DA, Kerwin E, Ayers T, et al. FLIGHT: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with COPD. Am J Respir Crit Care Med. 2015;192(9):1068-1079.
33. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6): 1484-1494.
34. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199-209.
35. Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. Efficacy and safety of coadministration of oncedaily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis. 2014;9:215-228.
36. Celli B, Crater G, Kilbride S, et al. Oncedaily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981-991.
37. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472-486.
38. Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, doubleblind, placebo-controlled study. Respir Res. 2014;15:78.
39. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10): 1538-1546.
40. Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8(6):169-181.
41. Rabe R, Martinez F, Rodriguez-Roisin R, et al. PT003, a novel co-suspension MDI glycopyrronium/formoterol fixeddose combination is superior to monocomponents in patients with COPD. Abstract number #PA4363. Eur Respi. J. 2015;46, Supplement 59.
42. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12:161.
43. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-469.
44. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-Acting beta-Agonist/longacting muscarinic antagonist combinations in COPD: a network metaanalysis. Thorax. 2015;10:2495-2517.
45. Schlueter M, Gonzalez-Rojas N, Baldwin M, Groenke L, Voss F, Reason T. Comparative efficacy of fixeddose combinations of long-Acting muscarinic antagonists and long-Acting beta2-Agonists: a systematic review and network meta-Analysis. Ther Adv Respir Dis. 2016;10:89-104.
46. Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc). 2012;48(12): 785-794.
47. Krishnan JA, Schatz M, Apter AJ. A call for action: comparative effectiveness research in asthma. J Allergy Clin Immunol. 2011;127(1):123-127.
48. Deeks J, Higgins J, Altman D. Analysing data and undertaking meta-Analyses: Cochrane Handbook for Systematic Reviews of Interventions, version 5.1. 0 [updated March 2011]. Cochrane Handbook for Systematic Reviews of Interventions. 2011;5.